An increased risk of developing diabetes with tesamorelin (HbA1c level 6.5%) relative to placebo was observed [intent-to-treat hazard odds ratio of 3.3 (CI 1.4, 9.6)]
This is less emergency admission drama and more slow burn harm that shows up months later
Population-based studies suggest that clinically diagnosed gastroparesis in GLP-1 users appears uncommon, though precise incidence estimates vary by study methodology, population characteristics, and diagnostic criteria
Choose phentermine if you: Need a lower-cost appetite tool with fast impact Prefer a tablet over injections Want a short-term reset with coaching and accountability Consider GLP-1s if you: Aim for larger total body-weight loss and can tolerate injections or oral GLP-1 dosing Have metabolic comorbidities where GLP-1 therapy provides additional benefits Have coverage/savings that reduce out-of-pocket cost Are willing to make a permanent financial commitment, as all studies show a very high rate of weight regain when stopping GLP-1s
This synergy, combined with powerful GLP-1 appetite suppression, creates the most potent weight loss effect seen in any clinical trial to date
Then doctors noticed patients were losing weight, and the off-label prescribing exploded